Research programme: Parkinson's disease therapeutics - Blue Therapeutics
Latest Information Update: 17 May 2021
At a glance
- Originator Blue Therapeutics
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease